nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP3A4—bone cancer	0.635	1	CbGaD
Loperamide—CYP2B6—Cisplatin—bone cancer	0.036	0.295	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—bone cancer	0.0241	0.198	CbGbCtD
Loperamide—ABCB1—Cisplatin—bone cancer	0.0185	0.151	CbGbCtD
Loperamide—POMC—cranial nerve—bone cancer	0.0143	0.282	CbGeAlD
Loperamide—POMC—vertebral column—bone cancer	0.014	0.277	CbGeAlD
Loperamide—ABCB1—Doxorubicin—bone cancer	0.0124	0.101	CbGbCtD
Loperamide—ABCB1—Methotrexate—bone cancer	0.012	0.0982	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—bone cancer	0.0117	0.0956	CbGbCtD
Loperamide—CYP3A4—Doxorubicin—bone cancer	0.00741	0.0608	CbGbCtD
Loperamide—Megacolon toxic—Methotrexate—bone cancer	0.00715	0.162	CcSEcCtD
Loperamide—CALM1—trigeminal nerve—bone cancer	0.00546	0.108	CbGeAlD
Loperamide—CALM1—cranial nerve—bone cancer	0.00389	0.0768	CbGeAlD
Loperamide—Megacolon—Methotrexate—bone cancer	0.00363	0.0822	CcSEcCtD
Loperamide—POMC—connective tissue—bone cancer	0.00295	0.0583	CbGeAlD
Loperamide—POMC—spinal cord—bone cancer	0.00196	0.0386	CbGeAlD
Loperamide—Bullous eruption—Epirubicin—bone cancer	0.00141	0.0319	CcSEcCtD
Loperamide—Bullous eruption—Doxorubicin—bone cancer	0.00131	0.0296	CcSEcCtD
Loperamide—Clemastine—CYP3A4—bone cancer	0.000836	0.178	CrCbGaD
Loperamide—Anaphylactoid reaction—Cisplatin—bone cancer	0.000814	0.0184	CcSEcCtD
Loperamide—CALM2—connective tissue—bone cancer	0.000806	0.0159	CbGeAlD
Loperamide—CALM1—connective tissue—bone cancer	0.000802	0.0158	CbGeAlD
Loperamide—Ileus—Epirubicin—bone cancer	0.000788	0.0178	CcSEcCtD
Loperamide—OPRM1—spinal cord—bone cancer	0.000736	0.0145	CbGeAlD
Loperamide—Ileus—Doxorubicin—bone cancer	0.000729	0.0165	CcSEcCtD
Loperamide—CALM3—tendon—bone cancer	0.000705	0.0139	CbGeAlD
Loperamide—CALM3—bone marrow—bone cancer	0.000683	0.0135	CbGeAlD
Loperamide—CALM3—spinal cord—bone cancer	0.00068	0.0134	CbGeAlD
Loperamide—Toremifene—CYP3A4—bone cancer	0.000663	0.141	CrCbGaD
Loperamide—Darifenacin—CYP3A4—bone cancer	0.000596	0.127	CrCbGaD
Loperamide—Depressed level of consciousness—Methotrexate—bone cancer	0.000575	0.013	CcSEcCtD
Loperamide—CALM2—tendon—bone cancer	0.000554	0.0109	CbGeAlD
Loperamide—CALM1—tendon—bone cancer	0.000551	0.0109	CbGeAlD
Loperamide—Urinary tract disorder—Cisplatin—bone cancer	0.000538	0.0122	CcSEcCtD
Loperamide—CALM2—bone marrow—bone cancer	0.000537	0.0106	CbGeAlD
Loperamide—Urethral disorder—Cisplatin—bone cancer	0.000535	0.0121	CcSEcCtD
Loperamide—CALM2—spinal cord—bone cancer	0.000534	0.0105	CbGeAlD
Loperamide—CALM1—bone marrow—bone cancer	0.000534	0.0105	CbGeAlD
Loperamide—CALM1—spinal cord—bone cancer	0.000532	0.0105	CbGeAlD
Loperamide—Immune system disorder—Cisplatin—bone cancer	0.000493	0.0112	CcSEcCtD
Loperamide—Flatulence—Cisplatin—bone cancer	0.000468	0.0106	CcSEcCtD
Loperamide—Levomethadyl Acetate—CYP3A4—bone cancer	0.000448	0.0955	CrCbGaD
Loperamide—Clotrimazole—CYP3A4—bone cancer	0.000448	0.0955	CrCbGaD
Loperamide—Anaphylactoid reaction—Methotrexate—bone cancer	0.000447	0.0101	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—bone cancer	0.000424	0.00959	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—bone cancer	0.000418	0.00947	CcSEcCtD
Loperamide—Haloperidol—CYP3A4—bone cancer	0.000403	0.086	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000401	0.00909	CcSEcCtD
Loperamide—Discomfort—Cisplatin—bone cancer	0.000399	0.00904	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—bone cancer	0.000392	0.00887	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000389	0.00882	CcSEcCtD
Loperamide—Anaphylactic shock—Cisplatin—bone cancer	0.000387	0.00877	CcSEcCtD
Loperamide—Dextropropoxyphene—CYP3A4—bone cancer	0.000387	0.0825	CrCbGaD
Loperamide—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000387	0.00876	CcSEcCtD
Loperamide—Fentanyl—CYP3A4—bone cancer	0.000383	0.0816	CrCbGaD
Loperamide—Nervous system disorder—Cisplatin—bone cancer	0.00038	0.0086	CcSEcCtD
Loperamide—Skin disorder—Cisplatin—bone cancer	0.000376	0.00852	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—bone cancer	0.00037	0.00837	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000364	0.00825	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—bone cancer	0.000352	0.00798	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—bone cancer	0.000342	0.00775	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000337	0.00764	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000334	0.00757	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—bone cancer	0.000333	0.00755	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00033	0.00748	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—bone cancer	0.000326	0.00738	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—bone cancer	0.000312	0.00706	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000309	0.007	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—bone cancer	0.000295	0.00669	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—bone cancer	0.000293	0.00664	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—bone cancer	0.000289	0.00654	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000286	0.00648	CcSEcCtD
Loperamide—Hypersensitivity—Cisplatin—bone cancer	0.000285	0.00646	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—bone cancer	0.000283	0.00641	CcSEcCtD
Loperamide—Asthenia—Cisplatin—bone cancer	0.000278	0.00629	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—bone cancer	0.000277	0.00626	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—bone cancer	0.000274	0.00622	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—bone cancer	0.00027	0.00612	CcSEcCtD
Loperamide—Diarrhoea—Cisplatin—bone cancer	0.000265	0.006	CcSEcCtD
Loperamide—Tamoxifen—CYP3A4—bone cancer	0.000265	0.0565	CrCbGaD
Loperamide—Erythema multiforme—Epirubicin—bone cancer	0.000265	0.006	CcSEcCtD
Loperamide—Methadone—CYP3A4—bone cancer	0.000263	0.056	CrCbGaD
Loperamide—Urinary tract disorder—Doxorubicin—bone cancer	0.000256	0.00579	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—bone cancer	0.000254	0.00575	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—bone cancer	0.000253	0.00573	CcSEcCtD
Loperamide—Vomiting—Cisplatin—bone cancer	0.000246	0.00558	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—bone cancer	0.000245	0.00555	CcSEcCtD
Loperamide—Rash—Cisplatin—bone cancer	0.000244	0.00553	CcSEcCtD
Loperamide—Dermatitis—Cisplatin—bone cancer	0.000244	0.00553	CcSEcCtD
Loperamide—Flatulence—Epirubicin—bone cancer	0.00024	0.00544	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—bone cancer	0.000234	0.0053	CcSEcCtD
Loperamide—Nausea—Cisplatin—bone cancer	0.00023	0.00521	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—bone cancer	0.000222	0.00503	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00022	0.00499	CcSEcCtD
Loperamide—Discomfort—Methotrexate—bone cancer	0.000219	0.00496	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—bone cancer	0.000214	0.00485	CcSEcCtD
Loperamide—ABCB1—bone marrow—bone cancer	0.000213	0.00421	CbGeAlD
Loperamide—Anaphylactic shock—Methotrexate—bone cancer	0.000213	0.00481	CcSEcCtD
Loperamide—ABCB1—spinal cord—bone cancer	0.000212	0.00419	CbGeAlD
Loperamide—Nervous system disorder—Methotrexate—bone cancer	0.000208	0.00472	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—bone cancer	0.000206	0.00468	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000206	0.00467	CcSEcCtD
Loperamide—Discomfort—Epirubicin—bone cancer	0.000205	0.00464	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—bone cancer	0.000203	0.0046	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—bone cancer	0.000199	0.00451	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—bone cancer	0.000198	0.00449	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—bone cancer	0.000195	0.00442	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—bone cancer	0.000193	0.00438	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000191	0.00432	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—bone cancer	0.00019	0.0043	CcSEcCtD
Loperamide—Somnolence—Methotrexate—bone cancer	0.000189	0.00428	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—bone cancer	0.000188	0.00425	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—bone cancer	0.000187	0.00424	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—bone cancer	0.000184	0.00417	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000184	0.00416	CcSEcCtD
Loperamide—Fatigue—Methotrexate—bone cancer	0.000183	0.00415	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—bone cancer	0.000181	0.00409	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—bone cancer	0.000179	0.00405	CcSEcCtD
Loperamide—Somnolence—Epirubicin—bone cancer	0.000177	0.00401	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—bone cancer	0.000175	0.00397	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—bone cancer	0.000174	0.00394	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000172	0.00389	CcSEcCtD
Loperamide—Fatigue—Epirubicin—bone cancer	0.000172	0.00388	CcSEcCtD
Loperamide—Constipation—Epirubicin—bone cancer	0.00017	0.00385	CcSEcCtD
Loperamide—Urticaria—Methotrexate—bone cancer	0.000169	0.00382	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—bone cancer	0.000168	0.00381	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—bone cancer	0.000164	0.00371	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—bone cancer	0.000163	0.00368	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—bone cancer	0.000162	0.00367	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000159	0.0036	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—bone cancer	0.000159	0.00359	CcSEcCtD
Loperamide—Urticaria—Epirubicin—bone cancer	0.000158	0.00358	CcSEcCtD
Loperamide—Constipation—Doxorubicin—bone cancer	0.000157	0.00357	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—bone cancer	0.000157	0.00356	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—bone cancer	0.000157	0.00355	CcSEcCtD
Loperamide—Asthenia—Methotrexate—bone cancer	0.000153	0.00345	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000151	0.00341	CcSEcCtD
Loperamide—Pruritus—Methotrexate—bone cancer	0.00015	0.00341	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—bone cancer	0.000147	0.00332	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—bone cancer	0.000146	0.00331	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—bone cancer	0.000146	0.0033	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—bone cancer	0.000145	0.00329	CcSEcCtD
Loperamide—Asthenia—Epirubicin—bone cancer	0.000143	0.00323	CcSEcCtD
Loperamide—Pruritus—Epirubicin—bone cancer	0.000141	0.00319	CcSEcCtD
Loperamide—Dizziness—Methotrexate—bone cancer	0.000141	0.00318	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—bone cancer	0.000136	0.00308	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—bone cancer	0.000136	0.00307	CcSEcCtD
Loperamide—Vomiting—Methotrexate—bone cancer	0.000135	0.00306	CcSEcCtD
Loperamide—Rash—Methotrexate—bone cancer	0.000134	0.00304	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—bone cancer	0.000134	0.00303	CcSEcCtD
Loperamide—Headache—Methotrexate—bone cancer	0.000133	0.00302	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—bone cancer	0.000132	0.00299	CcSEcCtD
Loperamide—Dizziness—Epirubicin—bone cancer	0.000132	0.00298	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—bone cancer	0.00013	0.00295	CcSEcCtD
Loperamide—Vomiting—Epirubicin—bone cancer	0.000126	0.00286	CcSEcCtD
Loperamide—Nausea—Methotrexate—bone cancer	0.000126	0.00286	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—bone cancer	0.000126	0.00285	CcSEcCtD
Loperamide—Rash—Epirubicin—bone cancer	0.000125	0.00284	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—bone cancer	0.000125	0.00284	CcSEcCtD
Loperamide—Headache—Epirubicin—bone cancer	0.000125	0.00282	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—bone cancer	0.000122	0.00276	CcSEcCtD
Loperamide—Nausea—Epirubicin—bone cancer	0.000118	0.00268	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—bone cancer	0.000117	0.00265	CcSEcCtD
Loperamide—Rash—Doxorubicin—bone cancer	0.000116	0.00263	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—bone cancer	0.000116	0.00263	CcSEcCtD
Loperamide—Headache—Doxorubicin—bone cancer	0.000115	0.00261	CcSEcCtD
Loperamide—Nausea—Doxorubicin—bone cancer	0.000109	0.00248	CcSEcCtD
Loperamide—POMC—Signaling Pathways—MMP9—bone cancer	5.33e-05	0.000372	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—EGFR—bone cancer	5.31e-05	0.00037	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—MDM2—bone cancer	5.27e-05	0.000368	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—MDM2—bone cancer	5.27e-05	0.000368	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—EGFR—bone cancer	5.27e-05	0.000367	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—GNA11—bone cancer	5.27e-05	0.000367	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—EGFR—bone cancer	5.24e-05	0.000366	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—EGFR—bone cancer	5.19e-05	0.000362	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—MDM2—bone cancer	5.17e-05	0.00036	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—MDM2—bone cancer	5.17e-05	0.00036	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—EGFR—bone cancer	5.14e-05	0.000358	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—EGFR—bone cancer	5.14e-05	0.000358	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—SMO—bone cancer	5.1e-05	0.000355	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—EGFR—bone cancer	5.1e-05	0.000355	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—EGFR—bone cancer	5.1e-05	0.000355	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—EGFR—bone cancer	5.07e-05	0.000354	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—EGFR—bone cancer	5.07e-05	0.000354	CbGpPWpGaD
Loperamide—CALM3—B Cell Activation—EGFR—bone cancer	4.96e-05	0.000346	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—SMO—bone cancer	4.93e-05	0.000344	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—SMO—bone cancer	4.93e-05	0.000344	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RGS1—bone cancer	4.93e-05	0.000344	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GRM4—bone cancer	4.93e-05	0.000344	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—ATF1—bone cancer	4.9e-05	0.000341	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NDUFA12—bone cancer	4.89e-05	0.000341	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SMO—bone cancer	4.87e-05	0.000339	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.86e-05	0.000339	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—PLAU—bone cancer	4.83e-05	0.000337	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—EGFR—bone cancer	4.8e-05	0.000335	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—EGFR—bone cancer	4.8e-05	0.000335	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL3—bone cancer	4.78e-05	0.000333	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RGS1—bone cancer	4.77e-05	0.000333	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GRM4—bone cancer	4.77e-05	0.000333	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GRM4—bone cancer	4.77e-05	0.000333	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RGS1—bone cancer	4.77e-05	0.000333	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.75e-05	0.000331	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—PLAU—bone cancer	4.68e-05	0.000326	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—PLAU—bone cancer	4.68e-05	0.000326	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—GNA11—bone cancer	4.66e-05	0.000325	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TGFBR2—bone cancer	4.66e-05	0.000325	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.59e-05	0.00032	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.59e-05	0.00032	CbGpPWpGaD
Loperamide—CALM3—Disease—ENO2—bone cancer	4.54e-05	0.000316	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—GNA11—bone cancer	4.51e-05	0.000315	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—GNA11—bone cancer	4.51e-05	0.000315	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—GNA11—bone cancer	4.45e-05	0.00031	CbGpPWpGaD
Loperamide—CALM1—Disease—ENO2—bone cancer	4.39e-05	0.000306	CbGpPWpGaD
Loperamide—CALM2—Disease—ENO2—bone cancer	4.39e-05	0.000306	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IGF1R—bone cancer	4.38e-05	0.000305	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—EGFR—bone cancer	4.31e-05	0.0003	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GRM1—bone cancer	4.28e-05	0.000298	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL3—bone cancer	4.23e-05	0.000295	CbGpPWpGaD
Loperamide—CALM3—Disease—DHFR—bone cancer	4.21e-05	0.000293	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ATF1—bone cancer	4.14e-05	0.000288	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GRM1—bone cancer	4.14e-05	0.000288	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GRM1—bone cancer	4.14e-05	0.000288	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL3—bone cancer	4.09e-05	0.000285	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL3—bone cancer	4.09e-05	0.000285	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFBR2—bone cancer	4.08e-05	0.000285	CbGpPWpGaD
Loperamide—CALM2—Disease—DHFR—bone cancer	4.07e-05	0.000284	CbGpPWpGaD
Loperamide—CALM1—Disease—DHFR—bone cancer	4.07e-05	0.000284	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NT5C3A—bone cancer	4.05e-05	0.000282	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL3—bone cancer	4.04e-05	0.000281	CbGpPWpGaD
Loperamide—CALM3—Immune System—ATF1—bone cancer	3.96e-05	0.000276	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ENO2—bone cancer	3.91e-05	0.000272	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KIT—bone cancer	3.87e-05	0.00027	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL3—bone cancer	3.86e-05	0.000269	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IGF1R—bone cancer	3.84e-05	0.000268	CbGpPWpGaD
Loperamide—CALM1—Immune System—ATF1—bone cancer	3.83e-05	0.000267	CbGpPWpGaD
Loperamide—CALM2—Immune System—ATF1—bone cancer	3.83e-05	0.000267	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.82e-05	0.000267	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ENO2—bone cancer	3.8e-05	0.000265	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KIT—bone cancer	3.75e-05	0.000261	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KIT—bone cancer	3.75e-05	0.000261	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL3—bone cancer	3.74e-05	0.000261	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL3—bone cancer	3.74e-05	0.000261	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KIT—bone cancer	3.72e-05	0.000259	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ENO2—bone cancer	3.68e-05	0.000256	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ENO2—bone cancer	3.68e-05	0.000256	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—EGFR—bone cancer	3.65e-05	0.000255	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—DHFR—bone cancer	3.62e-05	0.000253	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TP53—bone cancer	3.62e-05	0.000252	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KIT—bone cancer	3.6e-05	0.000251	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KIT—bone cancer	3.6e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—EGFR—bone cancer	3.53e-05	0.000246	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—EGFR—bone cancer	3.53e-05	0.000246	CbGpPWpGaD
Loperamide—CALM3—Metabolism—DHFR—bone cancer	3.53e-05	0.000246	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFBR2—bone cancer	3.45e-05	0.000241	CbGpPWpGaD
Loperamide—CALM2—Metabolism—DHFR—bone cancer	3.41e-05	0.000238	CbGpPWpGaD
Loperamide—CALM1—Metabolism—DHFR—bone cancer	3.41e-05	0.000238	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GNA11—bone cancer	3.39e-05	0.000236	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ENO2—bone cancer	3.31e-05	0.00023	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GNA11—bone cancer	3.3e-05	0.00023	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IGF1R—bone cancer	3.25e-05	0.000226	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.21e-05	0.000224	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GNA11—bone cancer	3.19e-05	0.000222	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GNA11—bone cancer	3.19e-05	0.000222	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KIT—bone cancer	3.18e-05	0.000222	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CYP3A4—bone cancer	3.07e-05	0.000214	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—DHFR—bone cancer	3.07e-05	0.000214	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFBR2—bone cancer	3.05e-05	0.000213	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—MDM2—bone cancer	3.05e-05	0.000213	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SMO—bone cancer	3.01e-05	0.00021	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CYP3A4—bone cancer	2.99e-05	0.000208	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—BRAF—bone cancer	2.99e-05	0.000208	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFBR2—bone cancer	2.95e-05	0.000206	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFBR2—bone cancer	2.95e-05	0.000206	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—MDM2—bone cancer	2.95e-05	0.000206	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—MDM2—bone cancer	2.95e-05	0.000206	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—MDM2—bone cancer	2.93e-05	0.000204	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SMO—bone cancer	2.91e-05	0.000203	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SMO—bone cancer	2.91e-05	0.000203	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—EGFR—bone cancer	2.9e-05	0.000202	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CYP3A4—bone cancer	2.89e-05	0.000201	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CYP3A4—bone cancer	2.89e-05	0.000201	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ENO2—bone cancer	2.88e-05	0.000201	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GNA11—bone cancer	2.87e-05	0.0002	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—MDM2—bone cancer	2.83e-05	0.000197	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—MDM2—bone cancer	2.83e-05	0.000197	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KIT—bone cancer	2.79e-05	0.000194	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GNA11—bone cancer	2.76e-05	0.000192	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ENO2—bone cancer	2.71e-05	0.000189	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—DHFR—bone cancer	2.67e-05	0.000186	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GNA11—bone cancer	2.67e-05	0.000186	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GNA11—bone cancer	2.67e-05	0.000186	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—JUN—bone cancer	2.65e-05	0.000185	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GSTP1—bone cancer	2.63e-05	0.000183	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—BRAF—bone cancer	2.62e-05	0.000183	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CYP3A4—bone cancer	2.6e-05	0.000181	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.59e-05	0.00018	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—JUN—bone cancer	2.56e-05	0.000179	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—JUN—bone cancer	2.56e-05	0.000179	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ATF1—bone cancer	2.56e-05	0.000179	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GSTP1—bone cancer	2.56e-05	0.000178	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—EGFR—bone cancer	2.54e-05	0.000177	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—DHFR—bone cancer	2.52e-05	0.000176	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MDM2—bone cancer	2.5e-05	0.000174	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL3—bone cancer	2.5e-05	0.000174	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GNA11—bone cancer	2.5e-05	0.000174	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ATF1—bone cancer	2.48e-05	0.000173	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ATF1—bone cancer	2.48e-05	0.000173	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GSTP1—bone cancer	2.47e-05	0.000172	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GSTP1—bone cancer	2.47e-05	0.000172	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL3—bone cancer	2.42e-05	0.000168	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL3—bone cancer	2.42e-05	0.000168	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KIT—bone cancer	2.36e-05	0.000164	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GNA11—bone cancer	2.35e-05	0.000164	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP3A4—bone cancer	2.26e-05	0.000158	CbGpPWpGaD
Loperamide—CALM3—Immune System—KIT—bone cancer	2.25e-05	0.000157	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GSTP1—bone cancer	2.22e-05	0.000155	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—BRAF—bone cancer	2.21e-05	0.000154	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MDM2—bone cancer	2.19e-05	0.000153	CbGpPWpGaD
Loperamide—CALM1—Immune System—KIT—bone cancer	2.18e-05	0.000152	CbGpPWpGaD
Loperamide—CALM2—Immune System—KIT—bone cancer	2.18e-05	0.000152	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—JUN—bone cancer	2.18e-05	0.000152	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—EGFR—bone cancer	2.15e-05	0.00015	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFBR2—bone cancer	2.14e-05	0.000149	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP3A4—bone cancer	2.13e-05	0.000149	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MMP9—bone cancer	2.12e-05	0.000148	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—EGFR—bone cancer	2.08e-05	0.000145	CbGpPWpGaD
Loperamide—CALM3—Disease—KIT—bone cancer	2.08e-05	0.000145	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFBR2—bone cancer	2.07e-05	0.000144	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFBR2—bone cancer	2.07e-05	0.000144	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—EGFR—bone cancer	2.02e-05	0.00014	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—EGFR—bone cancer	2.02e-05	0.00014	CbGpPWpGaD
Loperamide—CALM2—Disease—KIT—bone cancer	2.01e-05	0.00014	CbGpPWpGaD
Loperamide—CALM1—Disease—KIT—bone cancer	2.01e-05	0.00014	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1R—bone cancer	2.01e-05	0.00014	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—EGFR—bone cancer	2e-05	0.000139	CbGpPWpGaD
Loperamide—CALM3—Disease—BRAF—bone cancer	1.96e-05	0.000136	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1R—bone cancer	1.94e-05	0.000136	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1R—bone cancer	1.94e-05	0.000136	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—bone cancer	1.94e-05	0.000135	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GSTP1—bone cancer	1.94e-05	0.000135	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—EGFR—bone cancer	1.94e-05	0.000135	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—EGFR—bone cancer	1.94e-05	0.000135	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—JUN—bone cancer	1.91e-05	0.000133	CbGpPWpGaD
Loperamide—CALM2—Disease—BRAF—bone cancer	1.89e-05	0.000132	CbGpPWpGaD
Loperamide—CALM1—Disease—BRAF—bone cancer	1.89e-05	0.000132	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—bone cancer	1.88e-05	0.000131	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—bone cancer	1.88e-05	0.000131	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP9—bone cancer	1.86e-05	0.000129	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MDM2—bone cancer	1.85e-05	0.000129	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTP1—bone cancer	1.82e-05	0.000127	CbGpPWpGaD
Loperamide—CALM3—Immune System—MDM2—bone cancer	1.78e-05	0.000124	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—bone cancer	1.77e-05	0.000124	CbGpPWpGaD
Loperamide—CALM1—Immune System—MDM2—bone cancer	1.72e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Immune System—MDM2—bone cancer	1.72e-05	0.00012	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EGFR—bone cancer	1.71e-05	0.000119	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—DHFR—bone cancer	1.65e-05	0.000115	CbGpPWpGaD
Loperamide—CALM3—Disease—MDM2—bone cancer	1.64e-05	0.000114	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—JUN—bone cancer	1.61e-05	0.000112	CbGpPWpGaD
Loperamide—CALM1—Disease—MDM2—bone cancer	1.59e-05	0.000111	CbGpPWpGaD
Loperamide—CALM2—Disease—MDM2—bone cancer	1.59e-05	0.000111	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—bone cancer	1.58e-05	0.00011	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—bone cancer	1.57e-05	0.000109	CbGpPWpGaD
Loperamide—CALM3—Immune System—JUN—bone cancer	1.54e-05	0.000108	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GNA11—bone cancer	1.54e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—bone cancer	1.53e-05	0.000107	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—bone cancer	1.53e-05	0.000107	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EGFR—bone cancer	1.5e-05	0.000105	CbGpPWpGaD
Loperamide—CALM2—Immune System—JUN—bone cancer	1.49e-05	0.000104	CbGpPWpGaD
Loperamide—CALM1—Immune System—JUN—bone cancer	1.49e-05	0.000104	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIT—bone cancer	1.46e-05	0.000102	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—bone cancer	1.44e-05	0.0001	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIT—bone cancer	1.41e-05	9.83e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIT—bone cancer	1.41e-05	9.83e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BRAF—bone cancer	1.37e-05	9.55e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—bone cancer	1.36e-05	9.48e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—bone cancer	1.33e-05	9.26e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—bone cancer	1.33e-05	9.24e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—bone cancer	1.33e-05	9.24e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—bone cancer	1.32e-05	9.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—bone cancer	1.28e-05	8.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—bone cancer	1.28e-05	8.96e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—bone cancer	1.28e-05	8.93e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—bone cancer	1.28e-05	8.93e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—bone cancer	1.27e-05	8.84e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—bone cancer	1.26e-05	8.78e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—bone cancer	1.21e-05	8.46e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—bone cancer	1.19e-05	8.32e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—bone cancer	1.17e-05	8.18e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—bone cancer	1.17e-05	8.18e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—bone cancer	1.15e-05	8.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—bone cancer	1.15e-05	8e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—bone cancer	1.12e-05	7.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—bone cancer	1.11e-05	7.74e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—bone cancer	1.11e-05	7.74e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—bone cancer	1.08e-05	7.56e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—bone cancer	1.08e-05	7.56e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—bone cancer	1.06e-05	7.42e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—bone cancer	1e-05	6.99e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JUN—bone cancer	9.98e-06	6.96e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—bone cancer	9.71e-06	6.77e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JUN—bone cancer	9.65e-06	6.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JUN—bone cancer	9.65e-06	6.73e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—bone cancer	9.45e-06	6.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—bone cancer	9.39e-06	6.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—bone cancer	9.39e-06	6.55e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—bone cancer	7.85e-06	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—bone cancer	7.59e-06	5.29e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—bone cancer	7.59e-06	5.29e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—bone cancer	6.59e-06	4.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—bone cancer	6.37e-06	4.44e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—bone cancer	6.37e-06	4.44e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—bone cancer	6.18e-06	4.31e-05	CbGpPWpGaD
